Press Releases

Press Releases

Date Title
01/31/20 Vaxart Announces Initiation of Coronavirus Vaccine Program
Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NasdaqGS:  VXRT), a clinical-stage biotechnology company developing oral recombinant
01/22/20 Results from Influenza Challenge Study Published in Lancet Infectious Diseases
Efficacy of Oral Tablet Vaccine Compares Favorably to Market-Leading Fluzone® SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced